| 複合語 | スコア |
|---|---|
| herpes zoster | 5183.506266798 |
| varicella zoster virus | 844.73314175926 |
| incidence of herpes zoster | 247.94188319859 |
| acute herpes zoster | 207.67493560408 |
| prevention of herpes zoster | 136.02390012756 |
| postherpetic neuralgia | 121.18240878588 |
| antiviral therapy | 115.39564810414 |
| episode of herpes zoster | 111.71086250133 |
| treatment of herpes | 103.76616750019 |
| n engl j med | 96.359922943661 |
| acute pain | 92.919707492375 |
| intravenous acyclovir | 72.376241554004 |
| varicella zoster virus vasculopathy | 69.705940248073 |
| episode of herpes | 67.398102831388 |
| immunocompromised patients | 66.79578440913 |
| pain of herpes zoster | 57.072232811117 |
| live attenuated zoster vaccine | 56.947538877484 |
| herpes zoster vaccine | 55.24745423471 |
| oral acyclovir | 54.99090833947 |
| active herpes zoster | 54.173494431106 |
| herpes zoster ophthalmicus | 51.637323988487 |
| herpes zoster presenting | 51.637323988487 |
| clinical diagnosis of herpes zoster | 51.375113151333 |
| acute episode of herpes zoster | 49.403876373697 |
| varicella vaccine | 46.331687411531 |
| use of herpes | 43.628299137764 |
| severe pain | 42.560804659612 |
| complications of herpes zoster | 42.051180674778 |
| uncomplicated herpes | 41.814001326102 |
| incidence of herpes | 41.684343947313 |
| zoster vaccine | 41.666107508744 |
| history of herpes zoster | 40.984571210074 |
| treatment of herpes zoster | 40.984571210074 |
| varicella zoster virus dna | 40.950757897684 |
| herpes zoster rash | 40.082524921175 |
| immunocompetent patients | 40.079761113877 |
| zoster efficacy study | 39.417088182472 |
| skin lesions | 38.934150409863 |
| severe herpes | 38.791653025852 |
| shingles vaccine | 38.170664872767 |
| immunization practices | 37.951284151613 |
| immunocompetent adults | 35.858543433572 |
| recombinant zoster vaccine | 35.281898729777 |
| had varicella | 35.204469471736 |
| severity of herpes zoster | 34.127162990056 |
| united states | 33.895612242702 |
| severe herpes zoster | 33.762044091568 |
| shingles prevention study group | 33.181441818535 |
| varicella zoster vaccination | 32.846322030069 |
| shingles prevention study | 32.449917580626 |
| disseminated herpes | 32.061953638604 |
| adjuvanted herpes zoster subunit vaccine | 31.77222345061 |
| ann intern med | 31.141969833037 |
| cases of herpes zoster | 31.006585322085 |
| clin infect dis | 30.739889190125 |
| acute retinal necrosis | 30.340013319898 |
| disseminated herpes zoster | 29.734675012037 |
| j infect dis | 29.575246175559 |
| management of herpes zoster | 28.980468226666 |
| subsequent herpes | 27.876000884068 |
| disease control | 26.560366072808 |
| therapy of herpes | 26.465878355799 |
| acute herpes | 26.465878355799 |
| early herpes zoster | 25.818661994244 |
| recurrent herpes zoster | 25.818661994244 |
| herpes zoster of childhood vaccination | 25.481160611561 |
| et al | 25.234737164239 |
| advisory committee | 24.973349415057 |
| varicella zoster infection | 24.756751207287 |
| dose of varicella vaccine | 24.5919113521 |
| developed herpes zoster | 24.131548372928 |
| diagnosing herpes zoster | 24.131548372928 |
| episodes of herpes zoster | 24.131548372928 |
| risk of herpes | 23.971901648529 |
| cutaneous lesions of herpes zoster | 23.837907593557 |
| herpes simplex virus | 23.469378262797 |
| low-dose acyclovir | 23.424041119829 |
| antiviral drugs | 22.925026663968 |
| antiviral treatment | 22.62189070204 |
| dissemination of varicella zoster virus | 22.328559072964 |
| central nervous system | 21.568098473556 |
| varicella zoster virus igg | 21.539883775495 |
| varicella zoster virus transmission | 21.539883775495 |
| transmission of varicella zoster virus | 21.539883775495 |
| efficacy of zoster vaccine | 20.943453264666 |
| possible varicella zoster | 20.91565822694 |
| cutaneous healing of herpes zoster | 20.435204196548 |
| harpaz r | 19.817003712138 |
| varicella zoster virus retinitis | 18.776005282236 |
| possibility of varicella zoster virus | 18.776005282236 |
| zosteriform herpes simplex | 18.751775539312 |
| family history of herpes zoster | 18.58255614553 |
| oral antiviral therapy | 18.558378711077 |
| varicella vaccination program | 18.367718043369 |
| neuralgic pain | 18.350726547188 |
| live attenuated varicella zoster virus vaccine | 18.111232638103 |
| multifocal vasculopathy | 17.773539825992 |
| live zoster vaccine | 17.640949364888 |
| oral acyclovir therapy | 16.922206158072 |
| cutaneous healing | 16.757054048864 |
| percent of patients | 16.647165801151 |
| history of zoster rash | 16.622829872088 |
| disseminated zoster | 16.451644568508 |
| influenza vaccine | 16.214401857684 |
| zoster vaccine introduction | 16.201199197581 |
| complication rates of herpes zoster | 16.198145541661 |
| population-based study | 15.954887690835 |
| vaccine group | 15.937130414921 |
| oral treatment of herpes | 15.92383273608 |
| differential diagnosis of herpes zoster | 15.833161478903 |
| immune system | 15.79288815543 |
| herpes simplex virus infection | 15.692026165119 |
| duration of herpes | 15.424933085974 |
| hours of lesion onset | 15.139721272633 |
| history of varicella | 14.801656089846 |
| chickenpox virus | 14.742090873255 |
| ocular involvement | 14.325905783504 |
| trigeminal zoster | 14.303746543502 |
| ischemic lesions | 14.042083915924 |
| introduction of zoster vaccination | 14.001630789771 |
| safety of herpes | 13.938000442034 |
| ocular complications | 13.759162513002 |
| dermatomal zoster | 13.311136036748 |
| localized zoster | 13.311136036748 |
| live attenuated herpes | 13.197398237193 |
| collaborative famciclovir herpes zoster study group | 12.637151777336 |
| reactivation of varicella zoster virus increases | 12.493890175145 |
| lass j | 12.183259109214 |
| serious adverse events | 11.912482232343 |
| schmader ke | 11.771323825531 |
| tolerability of herpes | 11.720414607511 |
| ocular inflammatory complications of herpes | 11.644979764212 |
| new recombinant zoster vaccine | 11.47866721188 |
| cutaneous lesions | 11.401079531087 |
| mild pain | 11.384850195244 |
| chronic pain | 11.384850195244 |
| attenuated zoster vaccination coverage | 11.380099575338 |
| live virus vaccine | 11.339001382966 |
| neurologic complications | 11.269252989045 |
| levin mj | 11.132630734855 |
| childhood varicella | 11.066819197003 |
| involved skin | 11.059433928161 |
| childhood varicella vaccination | 11.029235690267 |
| risk factors | 10.911407287692 |
| years of age | 10.63659179389 |
| wood mj | 10.63659179389 |
| pain control | 10.594796911844 |
| serologic testing | 10.583005244258 |
| severe cases of herpes | 10.411483427417 |
| acyclovir therapy | 10.047658220351 |
| vaccination program | 9.8984640076795 |
| previous zoster infection | 9.8636347990426 |
| natural history of herpes | 9.8363850920969 |
| central nervous system involvement | 9.7518455544798 |
| potential severity of shingles | 9.7110004981407 |
| typical symptoms of herpes | 9.5419832218598 |
| health care | 9.4762744410752 |
| everyday activities | 8.9442719099992 |
| clinical practice | 8.8534553576026 |
| late complication of herpes | 8.7632228696839 |
| acyclovir halts progression of herpes | 8.587954697497 |
| contralateral hemiparesis | 8.4852813742386 |
| long-term persistence of zoster vaccine efficacy | 8.2824004707631 |
| immunocompromised persons | 8.2390685756285 |
| virus transmission | 8.157402714005 |
| double-blind rct | 8.1324180324886 |
| severe acute pain | 8.0542871296697 |
| common indicator of herpes | 8.0103222774806 |
| recombinant shingles vaccine | 7.999674446048 |
| recurrent herpes simplex infection | 7.8851895052982 |
| one rct | 7.770060192334 |
| placebo-controlled trial | 7.7025702136862 |
| subunit vaccine | 7.6673172509553 |
| antiviral agents | 7.6416755546559 |
| normal renal function | 7.5595262993692 |
| visceral dissemination | 7.5446005780976 |
| median follow-up | 7.5446005780976 |
| systemic antiviral therapy | 7.4953678880267 |
| immune status | 7.4448388728168 |
| immunocompetent persons | 7.4155855021347 |
| am j med | 7.3446842811871 |
| live vaccine | 7.3256830029694 |
| acute disease | 7.2794618755762 |
| increased risk | 7.2742715251283 |
| intravenous acyclovir therapy | 7.2287728000983 |
| gilden d. neurological complications of varicella zoster virus reactivation | 7.226859299044 |
| safety profile of varicella vaccine | 7.1606173454213 |
| n z med j | 7.1599738063165 |
| adverse ocular complications | 7.0752101004428 |
| new lesion formation | 7.0752101004428 |
| topical antiviral therapy | 7.0627845845626 |
| oral analgesics | 6.9282032302755 |
| johnson gr | 6.9009799013736 |
| antiviral drug therapy | 6.8836401999298 |
| virus replication | 6.8595306999877 |
| duration of pain | 6.7694724277124 |
| anti?varicella zoster virus igg antibody | 6.711207761057 |
| bandlike rash | 6.700737917669 |
| history of rash | 6.700737917669 |
| imaging studies | 6.700737917669 |
| varicella conflicts | 6.6874030497642 |
| varicella seroprevalence | 6.6874030497642 |
| varicella vaccinees | 6.6874030497642 |
| other antiviral agents | 6.4942575804746 |
| infectious disease specialist | 6.4062018950577 |
| randomized trial of acyclovir | 6.4042231448869 |
| pain control measures | 6.3079768610042 |
| disseminated skin lesions | 6.3051701955963 |
| trigeminal nerve | 6.2603383202932 |
| clinical trials | 6.2603383202932 |
| skin diseases | 6.2191767310173 |
| lesions of patients | 6.160140576482 |
| treatment of patients | 6.160140576482 |
| concomitant antiviral therapy | 6.1326262302568 |
| optimal antiviral therapy | 6.1326262302568 |
| pain specialist | 6.1169088490625 |
| sutphin j | 6.0916295546068 |
| topical acyclovir | 6.0860922072299 |
| antiviral medications | 6.0772008873526 |
| pediatr infect dis j | 6.0671409520631 |
| health history | 6.0548002080702 |
| medicare part d | 6.0523429976916 |
| skin changes | 6.014990027444 |
| oxman mn | 6 |
| cochrane database syst rev | 5.9906903399616 |
| other complications | 5.9245132753306 |
| low-dose oral acyclovir | 5.9036187547454 |
| introduction of varicella vaccination programs | 5.8856619127654 |
| severe allergy | 5.8856619127654 |
| chickenpox vaccine | 5.8259012604879 |
| skin biopsy | 5.7875960854994 |
| 2-shot varicella vaccine series | 5.7237619056446 |
| antiviral drugs famciclovir | 5.6945454450228 |
| physical examination | 5.5663153674275 |
| retinal necrosis | 5.5663153674275 |
| domingo j | 5.5044086707916 |
| fingeroth j | 5.5044086707916 |
| taylor j | 5.5044086707916 |
| storek j | 5.5044086707916 |
| marley j | 5.5044086707916 |
| yang j | 5.5044086707916 |
| crooks j | 5.5044086707916 |
| listing j | 5.5044086707916 |
| diez-domingo j | 5.5044086707916 |
| decroix j | 5.5044086707916 |
| pennella-vaughan j | 5.5044086707916 |
| placebo group | 5.4711295994695 |
| double-blind clinical trial | 5.4197492421882 |
| around-the-clock pain control | 5.4146047111091 |
| j clin virol | 5.399676491374 |
| zhou m | 5.3706992285653 |
| chlibek r | 5.3446902355676 |
| mmwr morb mortal wkly rep | 5.3345372167932 |
| other antiviral treatments | 5.3135289660276 |
| confirmatory laboratory testing | 5.2733493302731 |
| systematic review | 5.26429605181 |
| severe ear pain | 5.252546217199 |
| 10.8 percent of vaccine recipients | 5.2169309429792 |
| cunningham al | 5.1510191538028 |
| pain resolution | 5.1436867236104 |
| cessation of pain | 5.1436867236104 |
| unrelenting pain | 5.1436867236104 |
| pain relief | 5.1436867236104 |
| zoster?associated pain | 5.1436867236104 |
| prodromal pain | 5.1436867236104 |
| persistent pain | 5.1436867236104 |
| protracted pain | 5.1436867236104 |
| prolonged pain | 5.1436867236104 |
| zoster-associated pain | 5.1436867236104 |
| controlled clinical trials | 5.1395931737013 |
| development of skin lesions | 5.1170399378161 |
| antiviral prophylaxis | 5.1102964409515 |
| rash severity | 5.0914597900437 |
| other serious complications | 5.0830352786163 |
| studies of patients | 5.0099701392346 |
| infectious diseases collaborative antiviral study group | 4.9736700491369 |
| rash healing | 4.9242980521049 |
| vaccine component | 4.8989794855664 |
| family history of shingles | 4.8555002490703 |
| had shingles | 4.8339055525626 |
| clinical trials of rzv | 4.803747820704 |
| pharmacokinetic characteristics | 4.7568284600109 |
| contact dermatitis | 4.7568284600109 |
| onset of rash | 4.7381372205376 |
| bacterial superinfection | 4.6806946386414 |
| patient information | 4.6806946386414 |
| viral culture | 4.6806946386414 |
| lack of awareness | 4.6806946386414 |
| j cutan med surg | 4.6248450950756 |
| other symptoms | 4.5799756509618 |
| wilhelmus k | 4.5590141139096 |
| larussa p | 4.5590141139096 |
| kawai k | 4.5590141139096 |
| injection site | 4.5590141139096 |
| seasonal influenza vaccine | 4.5298688016454 |
| inactivated influenza vaccine | 4.5298688016454 |
| pine study | 4.4721359549996 |
| combined acyclovir | 4.4496055862541 |
| acyclovir fs | 4.4496055862541 |
| clinical appearance | 4.4267276788013 |
| late ocular inflammatory complications | 4.4111669921668 |
| limited skin involvement | 4.4036997674034 |
| skin disorders | 4.3976220398999 |
| skin inflammation | 4.3976220398999 |
| uninvolved skin | 4.3976220398999 |
| balfour hh jr | 4.3644945438869 |
| neurologic symptoms | 4.3558771746929 |
| oral valacyclovir | 4.3558771746929 |
| randomized trial | 4.331473541336 |
| early pain management | 4.2975746072033 |
| hwang sj | 4.2813902858562 |
| liesegang t | 4.2813902858562 |
| laboratory studies | 4.2813902858562 |
| lal h | 4.2813902858562 |
| serologic antibodies | 4.2813902858562 |
| forszpaniak c | 4.2813902858562 |
| johnson rw | 4.2813902858562 |
| three clinical trials | 4.2796527757347 |
| prospective clinical trials | 4.2796527757347 |
| few isolated skin lesions | 4.256307646096 |
| varicella-zoster virus dna | 4.2513258303959 |
| nondrug measures | 4.2294850537623 |
| acute disease phase | 4.2160379991699 |
| zoe-70 study group | 4.2140337012003 |
| zoe-50 study group | 4.2140337012003 |
| serious adverse effects | 4.1998684144302 |
| severe symptoms | 4.1617914502878 |
| polymerase chain reaction | 4.1601676461038 |
| adjacent dermatomes | 4.1195342878142 |
| same time | 4.1195342878142 |
| topical antiviral preparations | 4.1034303767613 |
| infectious complications | 4.090623489235 |
| potential ocular involvement | 4.0898524685786 |
| shingles vaccines | 4.0648138508249 |
| aggressive pain management | 4.0167507341439 |
| betts rf | 4 |
| large area of skin involvement | 3.9422986842475 |
| increased skin sensitivity | 3.9398401381041 |
| reynolds ma | 3.9359793425309 |
| vaccination decisions | 3.9359793425309 |
| bean b | 3.9359793425309 |
| zhang jh | 3.9359793425309 |
| tyring sk | 3.9359793425309 |
| does childhood vaccination | 3.9148676411689 |
| other possible symptoms | 3.9002320242577 |
| central nervous system angiitis | 3.8587145198412 |
| clear cause of shingles | 3.8538131016031 |
| acute vision changes | 3.8538131016031 |
| bacterial infection | 3.8512851068431 |
| oral corticosteroids | 3.8336586254776 |
| potential use | 3.8336586254776 |
| postherpetic neuralgia?fewer patients | 3.822602143583 |
| uncontrolled clinical trials | 3.8127371719878 |
| hospital infection control practices advisory committee | 3.80596150237 |
| such neurologic complications | 3.8027429028336 |
| prednisone therapy | 3.7976578442319 |
| common adverse effects | 3.7416573867739 |
| whitley rj | 3.7224194364084 |
| facial nerve | 3.7224194364084 |
| percentage of children | 3.7224194364084 |
| clinical outcome | 3.7224194364084 |
| clinical presentation | 3.7224194364084 |
| hospital rooms | 3.7224194364084 |
| kim dk | 3.7224194364084 |
| mckendrick mw | 3.7224194364084 |
| first division | 3.7224194364084 |
| seward jf | 3.7224194364084 |
| anecdotal experience | 3.7224194364084 |
| safety trial | 3.6423205736757 |
| weakened immune system | 3.6342411856643 |
| typical rash | 3.6002057436785 |
| follow-up studies | 3.6002057436785 |
| double-blind randomized controlled trial | 3.5520935491791 |
| initial therapy | 3.5341188430494 |
| improved therapy | 3.5341188430494 |
| j am geriatr soc | 3.4904525651001 |
| studies of recipients | 3.4820045452271 |
| tricyclic antidepressants | 3.4641016151377 |
| oral prednisone | 3.4641016151377 |
| appropriate specialists | 3.4641016151377 |
| age-related weakening | 3.4641016151377 |
| air samples | 3.4641016151377 |
| freezer storage | 3.4641016151377 |
| laskin ol | 3.4641016151377 |
| immunization schedule | 3.4641016151377 |
| initial treatment | 3.4641016151377 |
| diabetes mellitus | 3.4641016151377 |
| steinberg sp | 3.4641016151377 |
| use of corticosteroids | 3.4641016151377 |
| bialek sr | 3.4641016151377 |
| atypical presentations | 3.4641016151377 |
| global perspective | 3.4641016151377 |
| yawn bp | 3.4641016151377 |
| foulks gn | 3.4641016151377 |
| dworkin rh | 3.4641016151377 |
| computed tomography | 3.4641016151377 |
| sy ls | 3.4641016151377 |
| national health | 3.4397906282504 |
| population?based cohort study | 3.4199518933534 |
| smith n | 3.3895612242702 |
| aintablian n | 3.3895612242702 |
| aggarwal n | 3.3895612242702 |
| erskine n | 3.3895612242702 |
| chen n | 3.3895612242702 |
| typical skin eruption | 3.3818572012642 |
| painful rash | 3.3503689588345 |
| characteristic rash | 3.3503689588345 |
| tyring s. open-label study of valacyclovir | 3.31445401734 |
| retinal detachment | 3.3097509196469 |
| cochrane review | 3.3097509196469 |
| retinal tissue | 3.3097509196469 |
| zostavax efficacy | 3.2531531233956 |
| common adverse effect of rzv | 3.2531531233956 |
| rzv group | 3.2531531233956 |
| disease course | 3.2237097954706 |
| risk of cancer | 3.2010858729437 |
| ¿ therapy | 3.1934368675747 |
| randomised controlled trial | 3.1911262493545 |
| health care professional | 3.1664800441388 |
| 89.8 percent | 3.1622776601684 |
| 97.2 percent | 3.1622776601684 |
| 61.1 percent | 3.1622776601684 |
| 99.2 percent | 3.1622776601684 |
| 8.9 percent | 3.1622776601684 |
| 19.3 percent | 3.1622776601684 |
| 9.0 percent | 3.1622776601684 |
| 17.5 percent | 3.1622776601684 |
| 66.5 percent | 3.1622776601684 |
| 51.3 percent | 3.1622776601684 |
| 1.4 percent | 3.1622776601684 |
| 25.7 percent | 3.1622776601684 |
| 90.6 percent | 3.1622776601684 |
| systematic review of incidence | 3.14083560495 |
| surveillance of vaccination coverage | 3.14083560495 |
| use steroids | 3.1301691601466 |
| successful treatment | 3.1301691601466 |
| overlap of lesions | 3.1301691601466 |
| u.s. adults | 3.1301691601466 |
| thorough history | 3.1301691601466 |
| nonhemorrhagic lesions | 3.1301691601466 |
| susceptible immunocompromised persons | 3.0861636884341 |
| limited cutaneous involvement | 3.0825813601419 |
| 97.3 percent of persons | 3.080070288241 |
| many patients | 3.080070288241 |
| cutaneous vesicles | 3.0628143136088 |
| cerebral vasculopathy | 3.0628143136088 |
| primary infection | 3.0628143136088 |
| common complication | 3.0274001040351 |
| wash rash | 3.0274001040351 |
| itchy rash | 3.0274001040351 |
| side effects | 3.0274001040351 |
| prospective studies | 3.0274001040351 |
| high efficacy | 3.0274001040351 |
| clinical slide set | 3.0261714988458 |
| painful red rash | 3.0182390421613 |
| retinal biopsy specimens | 2.9937951655239 |
| national immunization survey | 2.9937951655239 |
| zhang d | 2.9906975624424 |
| placebo-controlled trials | 2.9906975624424 |
| placebo-controlled trial of oxycodone | 2.9506927476736 |
| affected nerve | 2.9129506302439 |
| optimal use | 2.9129506302439 |
| systemic effects | 2.8925076085191 |
| low risk | 2.8925076085191 |
| 9.4 percent of recipients | 2.8925076085191 |
| 16.5 percent of recipients | 2.8925076085191 |
| percent of recipients | 2.8925076085191 |
| betts r | 2.8716217110259 |
| latent infection | 2.8502698827718 |
| other medicines | 2.8502698827718 |
| other benefits | 2.8502698827718 |
| few other diseases | 2.8429702849739 |
| visceral involvement | 2.8394115144337 |
| zhou d | 2.8284271247462 |
| hemiparesis contralateral | 2.8284271247462 |
| 1.5 g | 2.8284271247462 |
| mental status changes | 2.8210130123402 |
| vision changes | 2.8173132472613 |
| common systemic effects | 2.8077989890847 |
| kang y. vaccination coverage | 2.8057011040133 |
| national immunization survey-child | 2.7981664143395 |
| one side | 2.7831576837137 |
| ophthalmic symptoms | 2.7831576837137 |
| certain ophthalmologic complications | 2.766175108537 |
| pathogenesis of diffuse disease | 2.7494592739972 |
| department of health | 2.7355647997348 |
| superior efficacy | 2.7355647997348 |
| health professionals | 2.7355647997348 |
| life-threatening secondary bacterial infection | 2.677321285993 |
| meta-analysis of risk factors | 2.6546748825543 |
| erythematous maculopapular rash | 2.6366746651365 |
| use of gloves | 2.632148025905 |
| dosing schedules | 2.632148025905 |
| corticosteroid use | 2.632148025905 |
| first dose | 2.632148025905 |
| late complication | 2.632148025905 |
| additional laboratory | 2.632148025905 |
| blood test | 2.632148025905 |
| as-needed dosing | 2.632148025905 |
| afferent nerve | 2.632148025905 |
| dosing regimen | 2.632148025905 |
| contact isolation | 2.632148025905 |
| clin res ed | 2.6207413942089 |
| other signs | 2.5755095769014 |
| hiv infection | 2.5755095769014 |
| recommended immunization schedule | 2.5697965868507 |
| control hosp epidemiol | 2.5697965868507 |
| public health rep | 2.557759296802 |
| intravenous antivirals | 2.5457298950218 |
| histopathologic studies | 2.5457298950218 |
| immunocompetent hosts | 2.5457298950218 |
| topical corticosteroids | 2.5457298950218 |
| alternate diagnosis | 2.5148668593659 |
| examination of csf | 2.5148668593659 |
| examination of links | 2.5148668593659 |
| strokelike symptoms | 2.5148668593659 |
| current symptoms | 2.5148668593659 |
| gastrointestinal symptoms | 2.5148668593659 |
| ophthalmic involvement | 2.4989993994394 |
| cobo m | 2.4989993994394 |
| characteristic funduscopic examination | 2.4928828716784 |
| recent cochrane review | 2.4928828716784 |
| intraocular inflammatory changes | 2.4643818583473 |
| drug administration | 2.4494897427832 |
| cunningham a | 2.4494897427832 |
| supportive care | 2.4494897427832 |
| facial muscle weakness | 2.4494897427832 |
| o fhalloran a | 2.4494897427832 |
| ifle r | 2.4147364027664 |
| ashton r | 2.4147364027664 |
| kay r | 2.4147364027664 |
| farmer r | 2.4147364027664 |
| schlag r | 2.4147364027664 |
| gress r | 2.4147364027664 |
| merlin r | 2.4147364027664 |
| possible cause of tia | 2.401873910352 |
| bill part d directly?and | 2.3784142300054 |
| frequent dosing | 2.3784142300054 |
| kruszon-moran d | 2.3784142300054 |
| international blood | 2.3784142300054 |
| yankey d | 2.3784142300054 |
| immune response | 2.3784142300054 |
| vista trial investigators | 2.3672935308725 |
| anticholinergic side effects | 2.3490100793233 |
| median duration | 2.3403473193207 |
| age groups | 2.3403473193207 |
| systemic reactions | 2.3403473193207 |
| kurland mj | 2.3403473193207 |
| involved dermatomes | 2.3403473193207 |
| kenneth schmader | 2.3403473193207 |
| diagnostic challenges | 2.3403473193207 |
| dr. schmader | 2.3403473193207 |
| magnetic resonance imaging | 2.334815148678 |
| serious problems | 2.3003266337912 |
| intravenous ganciclovir | 2.3003266337912 |
| kim sj | 2.3003266337912 |
| peripheral nerve palsies | 2.2894284851067 |
| altered mental status | 2.2894284851067 |
| primary care providers | 2.2894284851067 |
| wade a | 2.2795070569548 |
| potential benefits | 2.2795070569548 |
| wollan p | 2.2795070569548 |
| epidural injection | 2.2795070569548 |
| vazquez m | 2.2581008643532 |
| douha m | 2.2581008643532 |
| babb-tarbox m | 2.2581008643532 |
| heng m | 2.2581008643532 |
| tomlinson m | 2.2581008643532 |
| simultaneous involvement | 2.2581008643532 |
| kovac m | 2.2581008643532 |
| tomblyn m | 2.2581008643532 |
| patel m | 2.2581008643532 |
| kropff m | 2.2581008643532 |
| permanent facial muscle weakness | 2.2461919979205 |
| three 7-day regimens of famciclovir | 2.2427067839403 |
| 3.2 years | 2.2360679774998 |
| 3.1 years | 2.2360679774998 |
| 3.7 years | 2.2360679774998 |
| tyring s | 2.2360679774998 |
| nutrition examination survey | 2.2209061548523 |
| active viral replication | 2.2209061548523 |
| side ipsilateral | 2.2133638394006 |
| second dose | 2.2133638394006 |
| proximate cause | 2.2133638394006 |
| young adults | 2.2133638394006 |
| rare patient | 2.2133638394006 |
| functional status | 2.2133638394006 |
| levin l | 2.2133638394006 |
| direct contact | 2.2133638394006 |
| marrow research | 2.2133638394006 |
| sacral area | 2.2133638394006 |
| anecdotal reports | 2.2133638394006 |
| weeks of onset | 2.2133638394006 |
| improved preservation of vision | 2.1822472719434 |
| mayo clin proc | 2.1822472719434 |
| curr eye res | 2.1822472719434 |
| mmwr recomm rep | 2.1544346900319 |
| national institute of allergy | 2.1544346900319 |
| single 0.65-ml dose | 2.1398263878673 |
| resonant impurity states | 2.1398263878673 |
| large surface area | 2.1398263878673 |
| simplified dosing schedules | 2.1398263878673 |
| cranial nerve ganglia | 2.1398263878673 |
| increased sensitivity | 2.1147425268811 |
| daily famciclovir | 2.1147425268811 |
| lack of evidence | 2.1147425268811 |
| diagnostic tests | 2.1147425268811 |
| anti-tnf-alpha agents | 2.1147425268811 |
| involved dermatome | 2.1147425268811 |
| compared valacyclovir | 2.1147425268811 |
| diagnostic procedures | 2.1147425268811 |
| lack of need | 2.1147425268811 |
| relative lack | 2.1147425268811 |
| general information | 2.1147425268811 |
| biol blood marrow transplant | 2.1039790110173 |
| peripheral blood stem cells | 2.1039790110173 |
| permanent pigment changes | 2.0927300685678 |
| viral strain identification | 2.0757816311124 |
| jumaan a | 2.0597671439071 |
| moore k | 2.0597671439071 |
| mruthyunjaya p | 2.0597671439071 |
| potential pregnancy | 2.0597671439071 |
| morton p | 2.0597671439071 |
| saddier p | 2.0597671439071 |
| sacral dermatomes | 2.0597671439071 |
| hunter p | 2.0597671439071 |
| herzer p | 2.0597671439071 |
| strangfeld a | 2.0597671439071 |
| sepkowitz k | 2.0597671439071 |
| durham va medical center | 2.0597671439071 |
| gnann jw | 2.0597671439071 |
| bhaskaran k | 2.0597671439071 |
| liebhaber a | 2.0597671439071 |
| isolation precautions | 2.0597671439071 |
| steroids?and persons | 2.0597671439071 |
| guo a | 2.0597671439071 |
| potential risks | 2.0597671439071 |
| blinded rct | 2.0597671439071 |
| third rct | 2.0597671439071 |
| pcr assay | 2.0597671439071 |
| potential barriers | 2.0597671439071 |
| red blisters | 2.0597671439071 |
| challenging cases | 2.0597671439071 |
| arora a | 2.0597671439071 |
| intact persons | 2.0597671439071 |
| rockwitz k | 2.0597671439071 |
| continued new vesicle formation | 2.0565711885958 |
| results of pcr assay | 2.0396489026555 |
| gnann jw jr | 2.0396489026555 |
| 0.5-ml intramuscular injection | 2.0396489026555 |
| focal neurologic findings | 2.0396489026555 |
| concomitant administration of zostavax | 2.0396489026555 |
| general practice | 2 |
| inferior pharmacokinetic characteristics | 2 |
| u.s. food | 2 |
| anti?tumor necrosis factor | 2 |
| primary dermatome | 2 |
| cerebral arteries | 2 |
| uptake of rzv | 2 |
| nondrug therapies | 2 |
| white je | 1.9679896712654 |
| zhang q | 1.9679896712654 |
| life-threatening allergy | 1.9679896712654 |
| sutphin je | 1.9679896712654 |
| hematopoietic cell transplantation recipients | 1.9668942118313 |
| duke university medical center | 1.9579730911015 |
| magnetic resonance angiography | 1.9441612972397 |
| richter c | 1.9343364202677 |
| johnson g | 1.9343364202677 |
| bakri sj | 1.9343364202677 |
| jacobsen sj | 1.9343364202677 |
| vesikari t | 1.9343364202677 |
| pilishvili t | 1.9343364202677 |
| soong sj | 1.9343364202677 |
| topical creams | 1.9343364202677 |
| topical capsaicin | 1.9343364202677 |
| tran h | 1.9343364202677 |
| weiss h | 1.9343364202677 |
| einsele h | 1.9343364202677 |
| common sentinel | 1.9343364202677 |
| gzoster h | 1.9343364202677 |
| chiller t | 1.9343364202677 |
| kiefe c | 1.9343364202677 |
| ulbricht c | 1.9343364202677 |
| claeys c | 1.9343364202677 |
| clayton t | 1.9343364202677 |
| disseminated rashes | 1.9343364202677 |
| adult u.s. population | 1.9063685859939 |
| middle cerebral artery | 1.9063685859939 |
| zhu c. corticosteroids | 1.9063685859939 |
| clear vesicles | 1.8612097182042 |
| epidural steroids | 1.8612097182042 |
| noncontiguous dermatomes | 1.8612097182042 |
| time frame | 1.8612097182042 |
| strict isolation | 1.8612097182042 |
| many people | 1.8612097182042 |
| previous exposure | 1.8612097182042 |
| role of corticosteroids | 1.8612097182042 |
| case reports | 1.8612097182042 |
| body fight | 1.8612097182042 |
| shpilberg o | 1.8612097182042 |
| over-the-counter medications | 1.8612097182042 |
| small children | 1.8612097182042 |
| immunogenicity profile | 1.8612097182042 |
| appearance of blisters | 1.8612097182042 |
| reports grants | 1.8612097182042 |
| placebo groups | 1.8612097182042 |
| several days | 1.8612097182042 |
| affected dermatome | 1.8612097182042 |
| morrison va | 1.8612097182042 |
| godeaux o | 1.8612097182042 |
| eye evaluation | 1.8612097182042 |
| additional therapies | 1.8612097182042 |
| high sensitivity | 1.8612097182042 |
| approved valacyclovir dosage | 1.8493111942973 |
| mmwr surveill summ | 1.8493111942973 |
| consistent diagnostic criterion | 1.8493111942973 |
| transient ischemic attacks | 1.8493111942973 |
| basic symptomatic measures | 1.8493111942973 |
| antimicrob agents chemother | 1.8493111942973 |
| short-term persistence substudy | 1.8171205928321 |
| small vessel vasculitis | 1.8171205928321 |
| short-acting narcotic analgesics | 1.7817974362807 |
| phys rev lett | 1.7817974362807 |
| american academy of ophthalmology | 1.7817974362807 |
| san miguel jf | 1.7817974362807 |
| stokley s | 1.7782794100389 |
| yeh s | 1.7782794100389 |
| aboutlabeti s | 1.7782794100389 |
| moeckesch b | 1.7782794100389 |
| nahlik je | 1.7782794100389 |
| kerzner b | 1.7782794100389 |
| medlineplus information | 1.7782794100389 |
| nagel ma | 1.7782794100389 |
| cerebrovascular events | 1.7782794100389 |
| dimopoulos ma | 1.7782794100389 |
| thorne je | 1.7782794100389 |
| auricle?indicate ramsay hunt syndrome | 1.7692284081335 |
| author thanks jennifer f. wilson | 1.7411011265923 |
| wade jc | 1.7320508075689 |
| over-the-counter medicines | 1.7320508075689 |
| preferred test | 1.7320508075689 |
| preferred alternative | 1.7320508075689 |
| 2-dose regimen | 1.7320508075689 |
| local reactions | 1.7320508075689 |
| as-needed basis | 1.7320508075689 |
| curr opin neurol | 1.6983813295649 |
| past several decades | 1.6983813295649 |
| mg/kg of body weight | 1.6983813295649 |
| mg of methylprednisolone acetate | 1.6983813295649 |
| van wijck aj | 1.6983813295649 |
| internal carotid artery | 1.6983813295649 |
| van essen ga | 1.6983813295649 |
| general feeling | 1.6817928305074 |
| toxic dermatitis | 1.6817928305074 |
| ambinder rf | 1.6817928305074 |
| eligible people | 1.6817928305074 |
| corey l | 1.6817928305074 |
| chamberlin cj | 1.6817928305074 |
| clusters of vesicles | 1.6817928305074 |
| rare disorder | 1.6817928305074 |
| research setting | 1.6817928305074 |
| ophthalmology consultation | 1.6817928305074 |
| stolker rj | 1.6817928305074 |
| previous version | 1.6817928305074 |
| high-dose steroids | 1.6817928305074 |
| rare occasions | 1.6817928305074 |
| positive results | 1.6817928305074 |
| smeeth l | 1.6817928305074 |
| subsequent pustulation | 1.6817928305074 |
| absence of pleocytosis | 1.6817928305074 |
| lymphocytic pleocytosis | 1.6817928305074 |
| kalkman cj | 1.6817928305074 |
| three times | 1.6817928305074 |
| ragozzino mw | 1.6817928305074 |
| acosta cj | 1.6817928305074 |
| mononuclear pleocytosis | 1.6817928305074 |
| bortezomib-based therapies | 1.6817928305074 |
| million people | 1.6817928305074 |
| prospective fashion | 1.6817928305074 |
| analgesic medications | 1.6817928305074 |
| wallace mr. detection | 1.5874010519682 |
| cool astringent soaks | 1.5874010519682 |
| comas j. observation | 1.5874010519682 |
| health-related quality of life | 1.5874010519682 |
| private insurance plans | 1.5874010519682 |
| english word gbelt | 1.5874010519682 |
| st sauver jl | 1.5874010519682 |
| sensory neurons | 1.5650845800733 |
| controlled-release oxycodone | 1.5650845800733 |
| types of vaccines | 1.5650845800733 |
| such manifestations | 1.5650845800733 |
| elam-evans ld | 1.5650845800733 |
| connor jd | 1.5650845800733 |
| 2-dose requirement | 1.5650845800733 |
| mg of bupivacaine | 1.5650845800733 |
| outpatient basis | 1.5650845800733 |
| standard precautions | 1.5650845800733 |
| localized sensations | 1.5650845800733 |
| adult populations | 1.5650845800733 |
| cobo lm | 1.5650845800733 |
| kurland lt | 1.5650845800733 |
| specific treatments | 1.5650845800733 |
| perry ta | 1.5650845800733 |
| latent state | 1.5650845800733 |
| susceptible infants | 1.5650845800733 |
| friedman dj | 1.5650845800733 |
| huff jc | 1.5650845800733 |
| cohen ji | 1.5650845800733 |
| shafran sd | 1.5650845800733 |
| bone cancer | 1.5650845800733 |
| schoenberger sd | 1.5650845800733 |
| rice as | 1.5650845800733 |
| lopez as | 1.5650845800733 |
| frequency increases | 1.5650845800733 |
| cheng e | 1.5650845800733 |
| williams ww | 1.5650845800733 |
| mcquillan gm | 1.5650845800733 |
| direct invasion | 1.5650845800733 |
| white race | 1.5650845800733 |
| gelb ld | 1.5650845800733 |
| similar syndrome | 1.5650845800733 |
| local anaesthetics | 1.5650845800733 |
| mcgill ji | 1.5650845800733 |
| virus?related vasculitis | 1.5650845800733 |
| perry ho | 1.5650845800733 |
| grohskopf la | 1.5650845800733 |
| dermatomal distribution | 1.5650845800733 |
| shapiro e | 1.5650845800733 |
| frank infarction | 1.5650845800733 |
| plant exposure | 1.5650845800733 |
| williams hm | 1.5650845800733 |
| galea sa | 1.5650845800733 |
| meyers jd | 1.5650845800733 |
| lee gm | 1.5650845800733 |
| weakened immunity | 1.5650845800733 |
| billing challenges | 1.5650845800733 |
| brain infarction | 1.5650845800733 |
| experienced ophthalmologist | 1.5650845800733 |
| sensory nerves | 1.5650845800733 |
| good alternative | 1.5650845800733 |
| li q | 1.5650845800733 |
| wollan pc | 1.5650845800733 |
| intravitreal antivirals | 1.5650845800733 |
| experienced physicians | 1.5650845800733 |
| mcneil sa | 1.5650845800733 |
| special considerations | 1.5650845800733 |
| crane la | 1.5650845800733 |
| cost?benefit considerations | 1.5650845800733 |
| looney dj | 1.5650845800733 |
| fluorescent antigen | 1.4142135623731 |
| harvey pr | 1.4142135623731 |
| disease-related immunosuppression | 1.4142135623731 |
| neural blockade | 1.4142135623731 |
| belongia ea | 1.4142135623731 |
| khuageva nk | 1.4142135623731 |
| lu pj | 1.4142135623731 |
| fact sheet | 1.4142135623731 |
| allogenic transplants | 1.4142135623731 |
| straus se | 1.4142135623731 |
| singleton ja | 1.4142135623731 |
| keatley rm | 1.4142135623731 |
| female sex | 1.4142135623731 |
| significant fever | 1.4142135623731 |
| dooling kl | 1.4142135623731 |
| moons kg | 1.4142135623731 |
| sharrar rg | 1.4142135623731 |
| chu cp | 1.4142135623731 |
| thomas sl | 1.4142135623731 |
| dorsal root | 1.4142135623731 |
| hales cm | 1.4142135623731 |
| riley le | 1.4142135623731 |
| mcdermott mp | 1.4142135623731 |
| barbano rl | 1.4142135623731 |
| hematogenous route | 1.4142135623731 |
| quantum-well structures | 1.4142135623731 |
| tseng hf | 1.4142135623731 |
| proximal branches | 1.4142135623731 |
| sweet ar | 1.4142135623731 |
| andersen pl | 1.4142135623731 |
| gershon aa | 1.4142135623731 |
| madkan vk | 1.4142135623731 |
| schmid ds | 1.4142135623731 |
| only contraindication | 1.4142135623731 |
| light touch | 1.4142135623731 |
| gebremeskel bg | 1.4142135623731 |
| known correlation | 1.4142135623731 |
| oligoclonal bands | 1.4142135623731 |
| nucleic acids | 1.4142135623731 |
| neurotrophic keratitis | 1.4142135623731 |
| average interval | 1.4142135623731 |
| hurley lp | 1.4142135623731 |
| t-cell count | 1.4142135623731 |
| ortega-sanchez ir | 1.4142135623731 |
| arbeit rd | 1.4142135623731 |
| pappas pg | 1.4142135623731 |
| lindley mc | 1.4142135623731 |
| rheumatoid arthritis | 1.4142135623731 |
| melton lj | 1.4142135623731 |
| joesoef mr | 1.4142135623731 |
| human services | 1.4142135623731 |
| bmj open | 1.4142135623731 |
| arterial stenosis | 1.4142135623731 |
| barbarash ra | 1.4142135623731 |
| cerebrospinal fluid | 1.4142135623731 |
| protein level | 1.4142135623731 |
| daley mf | 1.4142135623731 |
| vitreous humor | 1.4142135623731 |
| subacute delirium | 1.4142135623731 |
| lasting damage | 1.4142135623731 |
| hutchinson sign | 1.4142135623731 |
| opstelten w | 1.4142135623731 |
| schwarz tf | 1.4142135623731 |
| medline plus | 1.4142135623731 |
| loose-fitting clothing | 1.4142135623731 |
| boardman kd | 1.4142135623731 |
| beutner kr | 1.4142135623731 |
| sawyer mh | 1.4142135623731 |
| mandal bk | 1.4142135623731 |
| chaves ss | 1.4142135623731 |
| shanabrook bv | 1.4142135623731 |
| likelihood of adherence | 1.4142135623731 |
| mri scans | 1.4142135623731 |
| simberkoff ms | 1.4142135623731 |
| 60-year period | 1.4142135623731 |
| wu yn | 1.4142135623731 |
| hill ha | 1.4142135623731 |
| auditory canal | 1.4142135623731 |
| multiple myeloma | 1.4142135623731 |
| pregnant women | 1.4142135623731 |
| out-of-pocket payments | 1.4142135623731 |
| tool kit | 1.4142135623731 |
| clinician look | 1.4142135623731 |
| garner js | 1.4142135623731 |
| north carolina | 1.4142135623731 |
| murray av | 1.4142135623731 |
| burden of illness | 1.4142135623731 |
| mertz gj | 1.4142135623731 |
| ready availability | 1.4142135623731 |
| hearing impairments | 1.4142135623731 |
| submitted work | 1.4142135623731 |
| forbes hj | 1.4142135623731 |
| temporal increase | 1.4142135623731 |
American College of Physicians, Japan Chapter Cummunication Server